After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.
Tags: Johnson & Johnson
Johnson & Johnson to buy private drug developer for $1.75 billion
Johnson & Johnson (JNJ.N) agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.
Johnson & Johnson to seek buyer for medical device maker unit
Johnson & Johnson (JNJ.N) plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter.
IBM launches Watson system for research, hopes for breakthroughs
International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research.
Apps put fitness fans through short, sharp workouts
Fitness buffs who can't make it to the gym but still want to exercise can turn to apps for a short, intense workout when they are pressed for time. The U.S. Centers for Disease Control recommend that adults do at least 150 minutes of moderate aerobic activity weekly. But recent studies suggest even short bouts of exercise can have positive health effects.
Latest News
California, US-based software developing company Accelrys has acquired Ireland-based software business Qumas in a deal valued at $50 million to expand its products expansion and client base.
Washington-based tech company Microsoft Corp sold a record offering of USD8 billion of bonds in dollars and euros to fund general corporate purposes, according to regulatory filings today.
Top credit ranking Johnson & Johnson reportedly sold USD3.5 billion in a six-part bond issue, its first offering in the last two years. Proceeds from the deal will be used to pay the health care product manufacturer's outstanding debt.
US-based generic drug manufacturer Mylan and two Indian pharmaceutical firms are in talks to buy Chennai-based Bafna Pharmaceuticals for an undisclosed amount, according to two sources familiar with the transaction.
Only three potential buyers from at least five who expressed initial interest were left to bid for the Ortho Clinical Diagnostics business of healthcare firm Johnson & Johnson, according to sources interviewed by Bloomberg.
Sources name the Carlyle Group LP and a combined group from Danaher Corp and Blackstone Group LP to have successfully advanced to the final stage of sale negotiations for J&J's diagnostics unit
Healthcare company Johnson & Johnson stopped selling some of its products to Amazon.com because of complaints about the site's third party sellers.
Many private equity firms and partnerships are in the process of formulating their bids for diagnostic unit of Johnson&Johnson.
Johnson & Johnson received numerous preliminary offers from hedge funds interested in acquiring its Ortho Clinical Diagnostics unit, said a Reuters report.
